Oculus Innovative Sciences, Inc. Announces Acceptance of Three Abstracts on the use of Microcyn(R) Technology in Diabetic Foot Ulcers by DFCon 08
PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) announced that three abstracts, which relate to the safety and efficacy of Microcyn® Technology in the treatment of diabetic foot ulcers, have been peer reviewed and accepted by the faculty of DFCon 08, one of the world’s premier diabetic foot conferences. The accepted abstracts are: